Erica Kelly

Hematologist / Thrombosis doc @DalMedSchool | MD & Internal Medicine @MunMed

[Thrombosis Canada @ThrombosisCan]

Today is World Thrombosis Day! Visit https://t.co/eeqpjxWYNw to learn more and take action to prevent blood clots. Watch our posts throughout the day to learn more. Don't forget that there are landmarks across Canada being lit up in blue and red in honour of #WTDay24. Check our website to see if there is a location near you: https://t.co/bPwGygqXYw

[Erica Kelly @ericackelly]

We have the best hematology nurses in Halifax! 🩸❤️
@sudeeppappur

[Nova Scotia Health @HealthNS]

Recently the team on 8A at the QEII Health Sciences Centre hosted their second Daisy Award Celebration. Taylor Gaudette RN was awarded with the DAISY Award for Extraordinary Nurses. Learn more: https://t.co/hf3s9LHzzy

[Deborah Siegal @DebSiegal]

Got 5 minutes to spare? Last chance to take our survey about antithrombotic treatment of stroke in people with cancer. Have your say and help us narrow this knowledge gap.

You could win an iPad!

Click on this survey link to participate:  https://t.co/WS27HsQlmb

[Erica Kelly @ericackelly]

Happy World Thrombosis Day! #WTD2023 @ThrombosisCan

[Thrombosis Canada @ThrombosisCan]

Knowing the Facts About Venous Thrombosis Could Save Your Life. Take a look at this blog post and interview with Dr Deborah Siegal (@DebSiegal) in time for #WTDay23 https://t.co/RSlvyNuOTt

[Thrombosis Canada @ThrombosisCan]

Are you planning to attend Vascular 2023? Join these colleagues and participate in the great educational opportunities over 5 days. Register today: https://t.co/qhOUcvBTd1 #VASC23 @DrSoniaAnand1 @MarcCarrier1 @platelet144 @LanaCastellucci @DebSiegal @tsengeric

[CanVECTOR Network @canvector]

It’s the meetings, discussions, friendships and collaboration that only happen in person that makes #VASC23 the one conference not to be missed. Five days. Six hosts. And thousands of reasons to attend.

Learn more: https://t.co/Lynw100X84

[Erica Kelly @ericackelly]

Attending #VASC23? I can’t wait for you to join in the conversation with me and my vascular colleagues. Learn more about the scientific program here: https://t.co/O0kvLFEB7E

[Marc Carrier @MarcCarrier1]

New 2023 ACR/EULAR Antiphospholipid Syndrome (APS) Classification Criteria are out!
Patients need at least 3 points each from the clinical and lab domains (See below) to be classified as having APS. This will be very useful to clinicians :)
https://t.co/RyJ5F6zr1s
@isth

[Omar Abdel-Razek, MD, MSc, FACC @OmarARazek]

Our SR/MA of dobutamine vs milrinone in CS. No difference between the 2 in RCTs. A signal for decreased mortality with milrinone and shorter LOS with dobutamine in observational data worth examining in larger studies. @benhibbertMDPhD @rebeccamathewmd

https://t.co/Yev5GXZbpW

[Jared Freid @jtrain56]

Rihanna and I move the same amount when we dance. #SuperBowl

[Andrew Gantzer @gantzeac]

@acweyand My favorite is when my patient is profoundly iron deficient, but not yet anemic, and can't tolerate oral iron. Not covered. Have to wait until they're anemic. 🤦

[Marc Carrier @MarcCarrier1]

ASA seems to be non-inferior to LMWH in preventing death and associated with low incidence of VTE in patients with pelvic or acetabular fracture or extremity fractures needing surgery #MedTwitter
https://t.co/DwOijcBq5U
@canvector @ThrombosisCan

[Erica Kelly @ericackelly]

Excited for this. #ASH22

[CanVECTOR Network @canvector]

At 1:15PM, don't miss presentation #522 on "Rivaroxaban vs Apixaban for Treatment of Cancer-Associated VTE: A Head-to-Head Analysis of the US Cohort of the Observational Study in Cancer-Associated Thrombosis for Rivaroxaban" in room 291-292 at #ASH2022 !

https://t.co/nM9GuzbQOF

[Marc Carrier @MarcCarrier1]

Dr. @TzufeiWang demonstrated that among older adults with chronic kidney disease, DOAC use was associated with lower VTE and higher hemorrhage risk compared to LMWH following knee or hip arthroplasty at #ASH22
@canvector @ThrombosisCan

[Marc Carrier @MarcCarrier1]

Dr. Kovacs presenting the results of Catheter 3 study (N=70) at #ASH22
Apixaban showing promise in CVC-associated UEDVT in cancer patients with high preserved CVC function low risk of VTE (1.4%) and bleeding complications (MB 2.9% and CRNMB 5.7%).
@ThrombosisCan @canvector

[Saskia Middeldorp @MiddeldorpS]

Educational session in selected populations. Good talk on anticoagulation in women #ASH22. DO NOT STOP ORAL CONTRACEPTIVES AT TIME of START ANTICOAGULATION FOR VTE.

[Erica Kelly @ericackelly]

#ASH22 run with the Halifax crew #truecrit

[Deborah Siegal @DebSiegal]

The True 'Crit Canadian team is ready to run at #ASH22 to raise funds for @ASH_hematology

[World Thrombosis Day @thrombosisday]

A5: There are 10+ million cases of #VTE each year making it a leading cause of death and disability worldwide. VTE Risk Assessments can reduce these numbers by determining if patients are at risk of developing a #bloodclot and by providing proper prophylaxis. #WTDay22 #ClotChat